WASHINGTON — While researchers emphasize that the current sample size of administrative actions remains too small to draw definitive conclusions, early observational data from the first quarter of 2025 suggests that Food and Drug Administration food program director Kyle Diamantas may be regulating the food supply at rates marginally higher than a sugar pill.
A preprint study released Tuesday by the Harvard T.H. Chan School of Public Health examined the first ninety days of the Florida attorney’s tenure, noting a statistically significant, albeit slight, deviation from the complete regulatory apoptosis predicted by early models of Trump administration appointees. Prior to his confirmation, in vitro simulations of a corporate defense lawyer leading the FDA’s food division had forecast a 99.8% reduction in federal oversight.
However, authors of the study urge extreme caution in interpreting the findings. Confounding variables—such as career scientists momentarily hiding documents on his desk, or routine paperwork being signed by mistake—could easily account for the observed enforcement events, making it difficult to establish a causal link between Diamantas and actual governance.
We are tracking a handful of localized instances where a food recall was not actively suppressed, but we must be careful not to conflate an isolated warning letter with systemic regulatory intent.
The methodology of the Harvard study has also faced scrutiny within the broader medical community. Critics point out that the baseline "placebo" used in the comparative analysis was an empty leather chair in the FDA commissioner's office, which managed to issue zero recalls during the trial period. When adjusted for seasonal variations in bacterial outbreaks and the standard latency of bureaucratic inertia, Diamantas's regulatory performance falls well within the margin of error for a completely vacant office.
Pending peer review of the complete first-year dataset, public health officials recommend that consumers treat the American food supply with the standard dose of caution, advising that the theoretical presence of an FDA director does not yet warrant a shift in personal food-safety protocols.